Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pulmocide
Biotech
Pulmocide exits OPERA with evidence of antifungal efficacy
The data suggest the candidate can prevent and eradicate infections without causing the problems associated with existing systemic therapies.
Nick Paul Taylor
Apr 15, 2024 9:41am
Oncorus C-suite out the door—Chutes & Ladders
Jun 9, 2023 9:30am
Sanofi-backed Jeito snags $630M fund for 12-15 European biotechs
Sep 20, 2021 1:00am
Pulmocide eyes global phase 3 registration with fresh funds
May 26, 2021 2:47pm
EuroBiotech Report: AstraZeneca, Novartis, $30M round and more
Mar 23, 2017 9:49am
Ex-GSK team raises $30M for respiratory infection trials
Mar 20, 2017 7:08am
